This Insider Has Just Sold Shares In Insmed
Some Insmed Incorporated (NASDAQ:INSM) shareholders may be a little concerned to see that the Lead Independent Director, David Brennan, recently sold a substantial US$3.1m worth of stock at a price of US$124 per share. That sale reduced their total holding by 21% which is hardly insignificant, but far from the worst we've seen.
The Last 12 Months Of Insider Transactions At Insmed
The Independent Director, Leo Lee, made the biggest insider sale in the last 12 months. That single transaction was for US$15m worth of shares at a price of US$197 each. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. The good news is that this large sale was at well above current price of US$129. So it is hard to draw any strong conclusion from it.
Insmed insiders didn't buy any shares over the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!
See our latest analysis for Insmed
For those who like to find hidden gems this free list of small cap companies with recent insider purchasing, could be just the ticket.
Does Insmed Boast High Insider Ownership?
For a common shareholder, it is worth checking how many shares are held by company insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. It's great to see that Insmed insiders own 0.6% of the company, worth about US$175m. This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.
So What Does This Data Suggest About Insmed Insiders?
Insiders haven't bought Insmed stock in the last three months, but there was some selling. Looking to the last twelve months, our data doesn't show any insider buying. The company boasts high insider ownership, but we're a little hesitant, given the history of share sales. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. At Simply Wall St, we found 2 warning signs for Insmed that deserve your attention before buying any shares.
Of course Insmed may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.